Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification

Subanalysis of a prospective multicenter study

Takashi Miki, Toru Miyoshi, Kazuhiko Kotani, Kunihisa Kohno, Hirohiko Asonuma, Satoru Sakuragi, Yasushi Koyama, Kazufumi Nakamura, Hiroshi Itoh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and aims: Oxidized high-density lipoprotein (oxHDL) is characterized by reduced anti-inflammatory properties compared with HDL. However, the role of oxHDL in the pathogenesis of coronary artery calcification (CAC), a marker of subclinical atherosclerosis, remains unclear. We prospectively investigated the association between the change in oxHDL and progression of CAC in a substudy of a multicenter study. Methods: In the principal study, patients with a CAC score of 1–999 were treated with pitavastatin with/without eicosapentaenoic acid. Measurement of CAC with multidetector-row computed tomography and a blood test were performed at baseline and at the 1-year follow-up. In the principal study, the increase in CAC did not differ among treatment groups. In this substudy, patients were divided into two groups: CAC progression (change in Agatston score of >0) and no CAC progression. Results: In total, 140 patients were analyzed. The oxHDL level significantly decreased from 167 (132–246) at baseline to 122 (103–149) after treatment (median [25 th –75th percentile], U/ml) (p < 0.001). The annual change in CAC was significantly positively associated with changes in oxHDL (r = 0.17, p = 0.04), triglycerides (r = 0.17, p = 0.04), and high-sensitivity C-reactive protein (r = 0.22, p = 0.01) but was not associated with changes in low-density lipoprotein cholesterol or HDL-cholesterol. Multiple logistic analysis demonstrated that the decrease in oxHDL per 10 U/ml was independently associated with CAC progression (odds ratio, 0.95; 95% confidence interval, 0.90–0.99; p = 0.04). Conclusions: The decrease in oxHDL is associated with the attenuation of CAC progression, suggesting that oxHDL is a potential target for atherosclerosis prevention.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalAtherosclerosis
Volume283
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

HDL Lipoproteins
Multicenter Studies
Coronary Vessels
Prospective Studies
Atherosclerosis
Eicosapentaenoic Acid
Multidetector Computed Tomography
Hematologic Tests
C-Reactive Protein
LDL Cholesterol
HDL Cholesterol
Triglycerides
Anti-Inflammatory Agents
Odds Ratio
Confidence Intervals

Keywords

  • Atherosclerosis
  • Computed tomography
  • Coronary artery calcification
  • High-density lipoprotein
  • Oxidized lipoprotein

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification : Subanalysis of a prospective multicenter study. / Miki, Takashi; Miyoshi, Toru; Kotani, Kazuhiko; Kohno, Kunihisa; Asonuma, Hirohiko; Sakuragi, Satoru; Koyama, Yasushi; Nakamura, Kazufumi; Itoh, Hiroshi.

In: Atherosclerosis, Vol. 283, 01.04.2019, p. 1-6.

Research output: Contribution to journalArticle

@article{02bb897ea19f4509859a6ab1cdd14196,
title = "Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification: Subanalysis of a prospective multicenter study",
abstract = "Background and aims: Oxidized high-density lipoprotein (oxHDL) is characterized by reduced anti-inflammatory properties compared with HDL. However, the role of oxHDL in the pathogenesis of coronary artery calcification (CAC), a marker of subclinical atherosclerosis, remains unclear. We prospectively investigated the association between the change in oxHDL and progression of CAC in a substudy of a multicenter study. Methods: In the principal study, patients with a CAC score of 1–999 were treated with pitavastatin with/without eicosapentaenoic acid. Measurement of CAC with multidetector-row computed tomography and a blood test were performed at baseline and at the 1-year follow-up. In the principal study, the increase in CAC did not differ among treatment groups. In this substudy, patients were divided into two groups: CAC progression (change in Agatston score of >0) and no CAC progression. Results: In total, 140 patients were analyzed. The oxHDL level significantly decreased from 167 (132–246) at baseline to 122 (103–149) after treatment (median [25 th –75th percentile], U/ml) (p < 0.001). The annual change in CAC was significantly positively associated with changes in oxHDL (r = 0.17, p = 0.04), triglycerides (r = 0.17, p = 0.04), and high-sensitivity C-reactive protein (r = 0.22, p = 0.01) but was not associated with changes in low-density lipoprotein cholesterol or HDL-cholesterol. Multiple logistic analysis demonstrated that the decrease in oxHDL per 10 U/ml was independently associated with CAC progression (odds ratio, 0.95; 95{\%} confidence interval, 0.90–0.99; p = 0.04). Conclusions: The decrease in oxHDL is associated with the attenuation of CAC progression, suggesting that oxHDL is a potential target for atherosclerosis prevention.",
keywords = "Atherosclerosis, Computed tomography, Coronary artery calcification, High-density lipoprotein, Oxidized lipoprotein",
author = "Takashi Miki and Toru Miyoshi and Kazuhiko Kotani and Kunihisa Kohno and Hirohiko Asonuma and Satoru Sakuragi and Yasushi Koyama and Kazufumi Nakamura and Hiroshi Itoh",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.atherosclerosis.2019.01.032",
language = "English",
volume = "283",
pages = "1--6",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification

T2 - Subanalysis of a prospective multicenter study

AU - Miki, Takashi

AU - Miyoshi, Toru

AU - Kotani, Kazuhiko

AU - Kohno, Kunihisa

AU - Asonuma, Hirohiko

AU - Sakuragi, Satoru

AU - Koyama, Yasushi

AU - Nakamura, Kazufumi

AU - Itoh, Hiroshi

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background and aims: Oxidized high-density lipoprotein (oxHDL) is characterized by reduced anti-inflammatory properties compared with HDL. However, the role of oxHDL in the pathogenesis of coronary artery calcification (CAC), a marker of subclinical atherosclerosis, remains unclear. We prospectively investigated the association between the change in oxHDL and progression of CAC in a substudy of a multicenter study. Methods: In the principal study, patients with a CAC score of 1–999 were treated with pitavastatin with/without eicosapentaenoic acid. Measurement of CAC with multidetector-row computed tomography and a blood test were performed at baseline and at the 1-year follow-up. In the principal study, the increase in CAC did not differ among treatment groups. In this substudy, patients were divided into two groups: CAC progression (change in Agatston score of >0) and no CAC progression. Results: In total, 140 patients were analyzed. The oxHDL level significantly decreased from 167 (132–246) at baseline to 122 (103–149) after treatment (median [25 th –75th percentile], U/ml) (p < 0.001). The annual change in CAC was significantly positively associated with changes in oxHDL (r = 0.17, p = 0.04), triglycerides (r = 0.17, p = 0.04), and high-sensitivity C-reactive protein (r = 0.22, p = 0.01) but was not associated with changes in low-density lipoprotein cholesterol or HDL-cholesterol. Multiple logistic analysis demonstrated that the decrease in oxHDL per 10 U/ml was independently associated with CAC progression (odds ratio, 0.95; 95% confidence interval, 0.90–0.99; p = 0.04). Conclusions: The decrease in oxHDL is associated with the attenuation of CAC progression, suggesting that oxHDL is a potential target for atherosclerosis prevention.

AB - Background and aims: Oxidized high-density lipoprotein (oxHDL) is characterized by reduced anti-inflammatory properties compared with HDL. However, the role of oxHDL in the pathogenesis of coronary artery calcification (CAC), a marker of subclinical atherosclerosis, remains unclear. We prospectively investigated the association between the change in oxHDL and progression of CAC in a substudy of a multicenter study. Methods: In the principal study, patients with a CAC score of 1–999 were treated with pitavastatin with/without eicosapentaenoic acid. Measurement of CAC with multidetector-row computed tomography and a blood test were performed at baseline and at the 1-year follow-up. In the principal study, the increase in CAC did not differ among treatment groups. In this substudy, patients were divided into two groups: CAC progression (change in Agatston score of >0) and no CAC progression. Results: In total, 140 patients were analyzed. The oxHDL level significantly decreased from 167 (132–246) at baseline to 122 (103–149) after treatment (median [25 th –75th percentile], U/ml) (p < 0.001). The annual change in CAC was significantly positively associated with changes in oxHDL (r = 0.17, p = 0.04), triglycerides (r = 0.17, p = 0.04), and high-sensitivity C-reactive protein (r = 0.22, p = 0.01) but was not associated with changes in low-density lipoprotein cholesterol or HDL-cholesterol. Multiple logistic analysis demonstrated that the decrease in oxHDL per 10 U/ml was independently associated with CAC progression (odds ratio, 0.95; 95% confidence interval, 0.90–0.99; p = 0.04). Conclusions: The decrease in oxHDL is associated with the attenuation of CAC progression, suggesting that oxHDL is a potential target for atherosclerosis prevention.

KW - Atherosclerosis

KW - Computed tomography

KW - Coronary artery calcification

KW - High-density lipoprotein

KW - Oxidized lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=85061343038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061343038&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2019.01.032

DO - 10.1016/j.atherosclerosis.2019.01.032

M3 - Article

VL - 283

SP - 1

EP - 6

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -